Key Developments: Kyowa Hakko Kirin Co Ltd (4151.T)

4151.T on Tokyo Stock Exchange

1,445JPY
27 Feb 2015
Change (% chg)

¥1 (+0.07%)
Prev Close
¥1,444
Open
¥1,455
Day's High
¥1,455
Day's Low
¥1,440
Volume
1,159,000
Avg. Vol
1,516,254
52-wk High
¥1,510
52-wk Low
¥1,006

Search Stocks

Latest Key Developments (Source: Significant Developments)

Kyowa Hakko Kirin Co Ltd and Syndax Pharmaceuticals Inc announces license agreement to develop and commercialize Entinostat in Japan and Korea
Wednesday, 7 Jan 2015 07:00pm EST 

Kyowa Hakko Kirin Co Ltd and Syndax Pharmaceuticals Inc:Says that the companies have entered into a license agreement for the exclusive rights to develop and commercialize entinostat in Japan and Korea.Entinostat is a Class I selective histone deacetylase (HDAC) inhibitor being developed by Syndax in the United States and Europe in combination with hormone therapy for advanced breast cancer and immune therapy combinations in solid tumors.Under the terms of the agreement, Kyowa Hakko Kirin will pay Syndax a total of up to $100 million including an upfront fee of $25 million with a certain amount of an equity investment and potential development and commercial milestone payments.Syndax will manufacture and supply the product to Kyowa Hakko Kirin during the term of the agreement.  Full Article

ONO PHARMACEUTICAL CO LTD, Bristol-Myers Squibb and Kyowa Hakko Kirin announces Immuno-Oncology Clinical collaboration studying Opdivo (nivolumab) and Mogamulizumab in Advanced Solid Tumors
Wednesday, 10 Dec 2014 06:00am EST 

ONO PHARMACEUTICAL CO LTD, Bristol-Myers Squibb Co and Kyowa Hakko Kirin Co Ltd:Enters into a clinical trial collaboration agreement to conduct a Phase 1 combination study with Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor, and mogamulizumab, an anti-CCR4 antibody.Study will focus on evaluating the safety, tolerability and anti-tumor activity of combining Opdivo and mogamulizumab as a potential treatment option for patients with advanced or metastatic solid tumors.Study will be conducted by Ono and Kyowa Hakko Kirin.Additional details of the collaboration were not disclosed.  Full Article

Kyowa Hakko Kirin Co Ltd subsidiary completes fully acquire Archimedes Pharma
Tuesday, 5 Aug 2014 08:00pm EDT 

Kyowa Hakko Kirin Co Ltd:UK-based subsidiary ProStrakan Group plc completed fully acquire Archimedes Pharma on Aug. 5 (UK time), Archimedes Pharma became wholly owned subsidiary of ProStrakan Group plc as the result.Plan disclosed on July 11.  Full Article

Kyowa Hakko Kirin Co Ltd subsidiary to acquire Archimedes Pharma
Friday, 11 Jul 2014 03:00am EDT 

Kyowa Hakko Kirin Co Ltd:Subsidiary ProStrakan Group plc entered into an agreement with Novo A/S, a private limited liability company full owned by the Novo Nordisk Foundation, to buy entire stake of Archimedes Pharma, a specialty pharmaceutical company, for 230 million pounds.  Full Article

R&I affirms Kyowa Hakko Kirin Co Ltd's rating at "A+" and announces stable outlook
Tuesday, 8 Jul 2014 02:00am EDT 

Kyowa Hakko Kirin Co Ltd:Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A+".Rating outlook stable.  Full Article

Kyowa Hakko Kirin Co Ltd announces future development direction for bardoxolone methyl (RTA 402)
Wednesday, 2 Jul 2014 03:30am EDT 

Kyowa Hakko Kirin Co Ltd:The company has decided the future development direction in Japan for bardoxolone methyl (RTA 402), a small-molecule compound licensed from Reata Pharmaceuticals, Inc.Decided to continue developing this compound for CKD patients with type 2 diabetes with a particular emphasis on patient safety, and plans to evaluate both the safety and efficacy of bardoxolone methyl in a new Phase 2 clinical study to be performed in Japan, under the new direction.  Full Article

Kyowa Hakko Kirin announces termination of mogamulizumab licensing agreement with Amgen
Thursday, 17 Apr 2014 02:00am EDT 

Kyowa Hakko Kirin Co Ltd:To terminate licensing agreement in relation to mogamulizumab with Amgen Inc.Under the licensing agreement entered into on March 6, 2008, Amgen was granted exclusive rights to develop and commercialize Kyowa Hakko Kirin's humanized monoclonal antibody mogamulizumab in all non-oncology indications worldwide, except in Japan, China, Korea and Taiwan.  Full Article

Arqule Inc announces commencement of phase 3 clinical trial with Tivantinib in Hepatocellular Carcinoma by partner Kyowa Hakko Kirin in Japan
Tuesday, 4 Feb 2014 08:00am EST 

Arqule Inc:Says the announcement by its partner, Kyowa Hakko Kirin Co., Ltd of the initiation of a Phase 3 clinical trial evaluating tivantinib (ARQ 197) in Japanese patients with c-Met diagnostic-high inoperable hepatocellular carcinoma treated with one prior sorafenib therapy.  Full Article

Kyowa Hakko Kirin Co Ltd proposes year-end dividend for FY 2013
Thursday, 30 Jan 2014 07:00pm EST 

Kyowa Hakko Kirin Co Ltd:Year-end dividend per share of 12.50 Japanese Yen for FY 2013.FY 2012 year-end dividend of 10.00 Japanese Yen.  Full Article

Kyowa Hakko Kirin Co Ltd announces co-promotion partnership agreement
Thursday, 19 Dec 2013 08:30pm EST 

Kyowa Hakko Kirin Co Ltd:Says the company, LEO Pharma K.K. and LEO Pharma K.K.'s parent company LEO Pharma A/S entered into a distribution and co-promotion agreement on Dec. 19 for LEO Pharma's proprietary topical calcipotriol/betamethasone dipropionate combination product.Says LEO Pharma K.K. had filed for the manufacturing and marketing approval of this product for psoriasis vulgaris in Japan in August.Says LEO Pharma K.K. is responsible for supplying the product, and Kyowa Hakko Kirin is responsible for distribution and Medical Representatives (MRs) promotion of the product, and the two companies will jointly conduct marketing activities.  Full Article

Search Stocks